Acceso gratuito disponible

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors

Tanja Dolinsek

Tanja Dolinsek

Buscar este autor en
Sciendo|Google Scholar
Dolinsek, Tanja
, 
Lara Prosen

Lara Prosen

Buscar este autor en
Sciendo|Google Scholar
Prosen, Lara
, 
Maja Cemazar

Maja Cemazar

Buscar este autor en
Sciendo|Google Scholar
Cemazar, Maja
, 
Tjasa Potocnik

Tjasa Potocnik

Buscar este autor en
Sciendo|Google Scholar
Potocnik, Tjasa
 y 
Gregor Sersa

Gregor Sersa

Buscar este autor en
Sciendo|Google Scholar
Sersa, Gregor
  
19 jul 2016
Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors's Cover Image
Acerca de este artículo
Artículo anterior
Artículo siguiente
Cite
Descargar portada
Categoría del artículo: Research Article
Publicado en línea: 19 jul 2016
Páginas: 274 - 279
Recibido: 23 may 2016
Aceptado: 14 jun 2016
DOI: https://doi.org/10.1515/raon-2016-0042
Palabras clave
© 2016 Fazekas and Porvázsnyik, published by De Gruyter Open
This content is free.

Figure 1

Survival of melanoma cells after vemurafenib (VMF) treatment. Survival of (A) BRAF V600E mutated melanoma cells SK-MEL-28 and (B) non-mutated melanoma cells CHL-1.
Survival of melanoma cells after vemurafenib (VMF) treatment. Survival of (A) BRAF V600E mutated melanoma cells SK-MEL-28 and (B) non-mutated melanoma cells CHL-1.

Figure 2

Survival of BRAF V600E mutated SK-MEL-28 melanoma cells and non-mutated CHL-1 cells after ECT with bleomycin. BLM (bleomycin); BLM + EP (ECT with bleomycin). Dotted line represents the IC90 value.
Survival of BRAF V600E mutated SK-MEL-28 melanoma cells and non-mutated CHL-1 cells after ECT with bleomycin. BLM (bleomycin); BLM + EP (ECT with bleomycin). Dotted line represents the IC90 value.

Figure 3

Survival of BRAF V600E mutated SK-MEL-28 melanoma cells after concomitant treatment with ECT and vemurafenib. BLM (bleomycin); BLM + VMF (bleomycin and 0.5 pM vemurafenib); BLM + EP (ECT with bleomycin); BLM + EP + VMF (ECT with bleomycin and 0.5 pM vemurafenib). Dotted line represents the IC90 value.
Survival of BRAF V600E mutated SK-MEL-28 melanoma cells after concomitant treatment with ECT and vemurafenib. BLM (bleomycin); BLM + VMF (bleomycin and 0.5 pM vemurafenib); BLM + EP (ECT with bleomycin); BLM + EP + VMF (ECT with bleomycin and 0.5 pM vemurafenib). Dotted line represents the IC90 value.
Idioma:
Inglés
Calendario de la edición:
4 veces al año
Temas de la revista:
Medicina, Medicina Clínica, Medicina Interna, Hematología, oncología, Radiología
RSS Feed de revista